17/02/2026 Sanofi and Teva’s duvakitug Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in UC and CD Nektar Therapeutics announced a research collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165 in multiple sclerosis Sanofi and Teva’s duvakitug Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in UC and CD ( Ref ) Sanofi and Teva announced positive results from the Phase 2b RELIEVE UCCD LTE/NCT05668013 study of

16/02/2026 Roche announced positive Phase 3 results for Gazyva/Gazyvaro in primary membranous nephropathy Roche announced positive Phase 3 results for Gazyva/Gazyvaro in primary membranous nephropathy ( Ref ) Roche announced positive results from the Phase 3 MAJESTY/ NCT04629248 study which evaluated the efficacy and safety of Gazyva/Gazyvaro (obinutuzumab; anti-CD20) in patients with primary membranous nephropathy The study met its primary endpoint of complete remission at t

13/02/2026 Novartis announced Phase 3 data in adult patients with IgA nephropathy Novartis announced Phase 3 data in adult patients with IgA nephropathy ( Ref ) Novartis announced final results from its Phase 3 ALIGN/ NCT04573478 study which evaluated Vanrafia (atrasentan; an ETA receptor antagonist) in adult patients with IgA nephropathy (IgAN) The study demonstrated a slowing of kidney function decline in adult patients with IgAN The ALIGN study showed a difference of 2.39

12/02/2026 The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis ( Ref ) The European Commission approved Amgen’s Uplizna®(inebilizumab; anti-CD19 mAb) as an add-on treatment to standard therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (M

10/02/2026 US FDA accepted NDA and granted priority review for Takeda’s oveporexton as a potential first-in-class therapy for Narcolepsy Type 1 Evommune reported positive top-line data from Phase 2a POC trial of EVO301 in moderate-to-severe atopic dermatitis Kincell Bio partnered with Regcell to advance Treg cell therapies into clinical trials for autoimmune diseases US FDA accepted NDA and granted priority review for Takeda’s oveporexton as a potential first-in-class therapy

Welcome to another episode of Inline, brought to you by decodeMR. In this episode, we focus on colorectal cancer. According to the World Health Organization, colorectal cancer is the third most common cancer worldwide, accounting for nearly 10% of all cancer cases, and is the second leading cause of cancer-related deaths globally. To discuss this further, we spoke with Professor Art Hiranyakas, a colorectal surgeon at Bangkok Hospital, Thailand. Dr. Art Hiranyakas explained h